2つのサイトクロームP450を含むフォスラクトミシンのPKS後の調整
Hengyu Li1, Miao Sun1, Juan Zhao2
1School of Chemistry and Materials Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
Organic letters
|August 27, 2025
まとめ
研究者は,Streptomyces platensisのフォスラクトミシン経路を解明し,P450s PnT3とPnT7のような新しい誘導体と鍵となる酵素を特定しました. この研究は,タンパク質フォスファターゼ2A阻害剤の設計のための洞察を提供します.
科学分野:
- 自然製品の生物合成
- 酵素学
- 薬剤化学
背景:
- フォスラクトマイシンは,潜在的な治療用途を持つ生物活性天然製品です.
- フォスラクトマイシンのPKS後の調整経路は,まだ完全に理解されていません.
- Streptomyces platensisは二次代謝産物として知られている.
研究 の 目的:
- Streptomyces platensisのフォスラクトミシンポストポリケチド合成 (PKS) 調整経路を完全に解明する.
- フォスラクトマイシン改変に関与する酵素を特定し特徴づけること.
- タンパク質フォスファタゼ2A (PP2A) 阻害剤としてのフォスラクトミシン誘導体の構造-活性関係 (SAR) を確立する.
主な方法:
- in vivoの遺伝子不活性化試験 (pnT1-pnT7) とin vitroの生化学試験の組み合わせ
- サイトクロームP450酵素の識別と機能的特徴付け
- フォスラクトマイシン誘導体の生物学的活性の評価
主要な成果:
- 4つの新しい化合物を含む7つのフォスラクトマイシン派生体が特定されました.
- PnT3 (C- 8/ C- 25酸化) とPnT7 (C- 18水酸化) という2つの重要なサイトクロームP450酵素が特徴付けられました.
- C-9 リン酸群は活動に不可欠であり, ε-ラクトンと C-3 マロニル群は有害である.
結論:
- この研究では,PKS後のフォスラクトマイシンの調整経路が完全に解明されました.
- PnT3は,複雑な酸化変化を媒介する多用途のP450酵素として特定されました.
- この発見は,新しいPP2A阻害剤の設計に不可欠な構造-活性関係の基礎を提供する.
関連する概念動画
Drug Biotransformation: Overview
2.9K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.9K
Drug Metabolism: Phase II Reactions
4.1K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.1K
Allosteric Proteins-ATCase
5.9K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.9K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
79
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
79


